IOVA
NASDAQIovance Biotherapeutics Inc.
SectorHealth CareIndustryBiotechnology: Biological Products (No Diagnostic Substances)
Price$13.63-0.81 (-5.62%)
01:30 PM04:30 PM
News · 26 weeks580%
2026-04-192026-10-11
Mix2690d
- Insider10(38%)
- SEC Filings5(19%)
- Other6(23%)
- Earnings3(12%)
- Analyst1(4%)
- Offering1(4%)
Latest news
25 items- SECSEC Form 8-K filed by Iovance Biotherapeutics Inc.8-K - IOVANCE BIOTHERAPEUTICS, INC. (0001425205) (Filer)
- INSIDERSEC Form 4 filed by Chief Medical Officer Berkowitz Noah4 - IOVANCE BIOTHERAPEUTICS, INC. (0001425205) (Issuer)
- INSIDERSEC Form 3 filed by new insider Berkowitz Noah3 - IOVANCE BIOTHERAPEUTICS, INC. (0001425205) (Issuer)
- PRIovance Biotherapeutics Appoints Noah Berkowitz, M.D., Ph.D., as Chief Medical OfficerLeader in Global Drug Development of T Cell Therapies PHILADELPHIA, Oct. 01, 2026 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ:IOVA), a commercial biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (TIL) therapies for patients with cancer, today announced the appointment of Noah Berkowitz, M.D., Ph.D., as Chief Medical Officer (CMO), effective September 30, 2026. "We are pleased to welcome Noah to Iovance as we prepare for important development and regulatory milestones for our TIL platform across multiple solid tumor cancers," said Frederick Vogt, Ph.D., J.D., Interim President and Chief Executive Officer.
- PRHigh-Stakes October has these Biotechs Entering Crucial StretchDENVER, Sept. 29, 2026 (GLOBE NEWSWIRE) -- (247marketnews.com) -- The biotechnology market is heading into a catalyst-heavy stretch, with Iovance Biotherapeutics (NASDAQ:IOVA), NeOnc Technologies Holdings (NASDAQ:NTHI), and Summit Therapeutics (NASDAQ:SMMT), moving from promises and pipelines toward events that could materially reshape how investors view their businesses. Iovance Boosts 2026 Revenue Guidance as Amtagvi Demand Surges For Iovance (NASDAQ:IOVA), the headline is revenue. The company raised its full-year 2026 total revenue guidance to $410 million to $420 million, up $55 million at the midpoint from its previous $350 million to $370 million range. That new outlook implies nea
- SECIovance Biotherapeutics Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits8-K - IOVANCE BIOTHERAPEUTICS, INC. (0001425205) (Filer)
- PRIovance Biotherapeutics Raises Full Year 2026 Revenue Guidance to $410 to $420 MillionNew Guidance Represents an Increase of $55 Million at the Midpoint from the Prior Range of $350 to $370 Million Strong U.S. Demand for Amtagvi and Proleukin Drives Increased Outlook PHILADELPHIA, Sept. 29, 2026 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ:IOVA), a commercial biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (TIL) therapies for patients with cancer, today raised its full year 2026 total revenue guidance range to $410 to $420 million, driven by strong U.S. demand for Amtagvi® (lifileucel) and Proleukin. The midpoint represents an increase of $55 million, or ~15%, over the previous guidance ra
- ANALYSTGoldman resumed coverage on Iovance Biotherapeutics with a new price targetGoldman resumed coverage of Iovance Biotherapeutics with a rating of Buy and set a new price target of $15.00
- PRIovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)SAN CARLOS, Calif., Sept. 18, 2026 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) ("Iovance" or the "Company"), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte ("TIL") therapies for patients with cancer, today announced that on September 17, 2026 (the "Date of Grant"), the Company approved the grant of inducement stock options covering an aggregate of 179,750 shares of Iovance’s common stock to eighteen new, non-executive employees. The awards were granted under Iovance’s Amended and Restated 2021 Inducement Plan, which provides for the granting of equity awards to new employees of Iovance by the Com
- INSIDERInterim CEO & General Counsel Vogt Frederick G converted options into 15,626 shares and covered exercise/tax liability with 6,638 shares, increasing direct ownership by 2% to 595,447 units (SEC Form 4) to satisfy tax liability4 - IOVANCE BIOTHERAPEUTICS, INC. (0001425205) (Issuer)
- INSIDERChief Operating Officer Bilinsky Igor covered exercise/tax liability with 3,976 shares and converted options into 7,813 shares, increasing direct ownership by 3% to 142,074 units (SEC Form 4) to satisfy withholding tax4 - IOVANCE BIOTHERAPEUTICS, INC. (0001425205) (Issuer)
- INSIDERChief Regulatory Officer Puri Raj K. converted options into 9,766 shares and covered exercise/tax liability with 4,478 shares, increasing direct ownership by 2% to 256,364 units (SEC Form 4) (for withholding tax)4 - IOVANCE BIOTHERAPEUTICS, INC. (0001425205) (Issuer)
- PRIovance Biotherapeutics to Present at Upcoming ConferencesSAN CARLOS, Calif., Sept. 04, 2026 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ:IOVA), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (TIL) therapies for patients with cancer, today announced that senior leadership plans to present at the following upcoming conferences: Wells Fargo 21st Annual Healthcare ConferenceFireside Chat: September 10, 2026, at 11:00 a.m. ETBoston, MA H.C. Wainwright 28th Annual Global Investment ConferencePresentation: September 15, 2026, at 4:00 p.m. ETNew York, NY The live and archived webcast will be available at https://ir.iovance.com/news-events/events-presentations. Abo
- INSIDERSEC Form 4 filed by Iovance Biotherapeutics Inc.4 - IOVANCE BIOTHERAPEUTICS, INC. (0001425205) (Issuer)
- INSIDERChief Regulatory Officer Puri Raj K. covered exercise/tax liability with 2,508 shares and converted options into 5,470 shares, increasing direct ownership by 1% to 251,076 units (SEC Form 4) to cover taxes4 - IOVANCE BIOTHERAPEUTICS, INC. (0001425205) (Issuer)
- INSIDERChief Operating Officer Bilinsky Igor converted options into 8,789 shares and covered exercise/tax liability with 4,472 shares, increasing direct ownership by 3% to 138,237 units (SEC Form 4) (withholding tax)4 - IOVANCE BIOTHERAPEUTICS, INC. (0001425205) (Issuer)
- PRIovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)SAN CARLOS, Calif., Aug. 21, 2026 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) ("Iovance" or the "Company"), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte ("TIL") therapies for patients with cancer, today announced that on August 20, 2026 (the "Date of Grant"), the Company approved the grant of inducement stock options covering an aggregate of 240,135 shares of Iovance’s common stock to twenty new, non-executive employees. The awards were granted under Iovance’s Amended and Restated 2021 Inducement Plan, which provides for the granting of equity awards to new employees of Iovance by the Company’s
- INSIDERChief Commercial Officer Kirby Daniel Gordon converted options into 10,001 shares and covered exercise/tax liability with 2,436 shares, increasing direct ownership by 5% to 154,511 units (SEC Form 4) (withholding tax)4 - IOVANCE BIOTHERAPEUTICS, INC. (0001425205) (Issuer)
- INSIDERChief Financial Officer Roche Corleen M. converted options into 49,995 shares and covered exercise/tax liability with 21,238 shares (SEC Form 4) to cover taxes4 - IOVANCE BIOTHERAPEUTICS, INC. (0001425205) (Issuer)
- SECSEC Form SCHEDULE 13G filed by Iovance Biotherapeutics Inc.SCHEDULE 13G - IOVANCE BIOTHERAPEUTICS, INC. (0001425205) (Subject)
- SECIovance Biotherapeutics Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits8-K - IOVANCE BIOTHERAPEUTICS, INC. (0001425205) (Filer)
- PRWhy Investors Are Watching These Healthcare MoversDENVER, Aug. 06, 2026 (GLOBE NEWSWIRE) -- (https://247mnn.com/) – ClearOne (NASDAQ:CLRO), NeOnc Technologies (NASDAQ:NTHI), Iovance Biotherapeutics (NASDAQ:IOVA), and Ensysce Biosciences (NASDAQ:ENSC) are covered in today’s roundup. ClearOne Advances Toward Neurotechnology Transformation ClearOne (NASDAQ:CLRO) continues moving closer to completing its planned transformation into a neurotechnology company as new SEC filings remove several key uncertainties surrounding its pending acquisition of Cortigent, a wholly owned subsidiary of Vivani Medical (NASDAQ:VANI), which was first announced on July 2, as investors continue tracking milestones that could reshape the company's future. Clear
- SECSEC Form 10-Q filed by Iovance Biotherapeutics Inc.10-Q - IOVANCE BIOTHERAPEUTICS, INC. (0001425205) (Filer)
- SECIovance Biotherapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - IOVANCE BIOTHERAPEUTICS, INC. (0001425205) (Filer)
- PRIovance Biotherapeutics Reports Record Second Quarter 2026 Revenue of ~$99M, Business Achievements, and Corporate UpdatesU.S. Amtagvi Revenue Reaches ~$91M and Total Revenue Increased 66% Year-over-Year Gross Margin Increased to 56% Fast Track Designation (FTD) Granted by the FDA for Lifileucel in Soft Tissue Sarcomas SAN CARLOS, Calif., Aug. 06, 2026 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ:IOVA), a commercial biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (TIL) therapies for patients with cancer, today reported second quarter 2026 financial results, business achievements, and corporate updates. "Second-quarter revenue reached a record $99.3 million with gross margin of 56%, driven by continued U.S. Amtagvi demand,
IOVA FAQ
6 questionsWhat does Iovance Biotherapeutics Inc. do?
Iovance Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing cancer immunotherapy products to harness the power of a patient's immune system to eradicate cancer cells. It has six ongoing phase 2 clinical studies, including C-144-01, of its lead product candidate, lifileucel, for the treatment of metastatic melanoma; C-145-04, of its product candidate lifileucel for recurrent, metastatic, or persistent cervical cancer; and C-145-03, of its product candidate LN-145, for recurrent and/or metastatic head and neck squamous cell carcinoma. Iovance...Where does IOVA stock trade?
Iovance Biotherapeutics Inc. (IOVA) is listed on NASDAQ.What sector and industry is IOVA in?
Iovance Biotherapeutics Inc. operates in the Health Care sector, Biotechnology: Biological Products (No Diagnostic Substances) industry.What are analysts saying about IOVA?
Iovance Biotherapeutics Inc. has had 8 recent analyst actions on file. The most recent action was from Goldman: Buy with a $1500.00 price target on 2026-09-24.What companies are similar to IOVA?
Notable peers in the same industry include AMGN (Amgen Inc.), GILD (Gilead Sciences Inc.), MRNA (Moderna Inc.), ARGX (argenx SE), RVMD (Revolution Medicines Inc.). Compare IOVA side-by-side with any of them on Quantisnow.How can I track IOVA on Quantisnow?
Quantisnow aggregates Iovance Biotherapeutics Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow IOVA to receive live email and push alerts on every new disclosure.